Blood. 2006 March 1; 107(5): 2170–2179.
Figure 3. Overexpression of Ezh2 in HSCs. (A) WBC counts of mice given transplants with BM cells transduced with control () or Ezh2 () vectors (n = 11 recipients per group, 2 independent experiments). Mean values plus or minus standard error of the mean (SEM) are shown. (B) Chimerism at different time points after transplantation. The percentage of donor-derived transduced CD45.1+GFP+ WBCs is shown. Average values ± 1 SEM of 2 independent experiments are shown. (C) Ezh2 protein expression in the spleen about 120 days after primary transplantation of control or Ezh2 CD45.1 BM cells. (D) CAFC frequencies of sorted LSK GFP+ cells 120 days after primary transplantation (control, ; Ezh2, ). (E) Chimerism levels of secondary recipients, competitively transplanted with various ratios (2:1, ⋄; 1:1, ○; 1:2, □; 1:5, ▵) of transduced/nontransduced and freshly isolated BM cells, analyzed 3 months after transplantation. Values show data from individual recipients in 2 independent experiments (n = 35/group). (F) CRI calculated for CD45.1+GFP+ (transduced) versus CD45.1+GFP- (nontransduced) cells (see insert). Values (+ 1 SEM) are averages 3 months after secondary transplantation, based on 11 and 24 individual mice in the first and second experiment, respectively (control, ; Ezh2, ). (G) CRI calculated for transduced cells (CD45.1+GFP+) compared to freshly isolated BM cells (CD45.2+; see insert). Averages values (+ 1 SEM) of 11 and 24 individual mice of the first and second experiment, respectively, are shown (control, ; Ezh2, ). (H) LTRA frequencies in CD45.1+GFP+ (transduced) cell fractions calculated from limiting dilution analyses 3 months after secondary transplantation in 2 independent experiments (control, ; Ezh2, ).
PLoS Med. 2006 October; 3(10): e420.
Figure 7 Increased NRF2 Activity Confers Chemoresistance BEAS2B cells and cancer cells were exposed to etoposide (A) or carboplatin (B) for 72 h, and viable cells were determined by MTT assay. BEAS2B cells displayed enhanced sensitivity whereas cancer cells with dysfunctional KEAP1 activity demonstrated reduced chemosensitivity to etoposide and carboplatin treatment. Data are presented as percentage of viable cells relative to the vehicle-treated control. Data are the mean of eight independent replicates, combined to generate the mean 卤 SD for each concentration.
Reproductive Biology and Endocrinology 2008, 6:42
Relative mRNA expression of Slα (○) and Slβ (●) in the pituitary and slr (▼) in the ovary of Atlantic salmon female broodstock from August 2003 to December 2004. Each point represents mean ± SEM of n = 6–10 per date and * denotes significance at P < 0.0166. Relative transcription levels were normalized to ef1α and compared to the initial August sample. Benedet et al. Reproductive Biology and Endocrinology 2008 6:42
The Journal of Neuroscience, July 4, 2007, 27(27):7083-7093
Figure 2. A, Effect of LPS on infarct volume with or without pretreatment with AG. B, Intraischemic CBF in the groups of mice presented in A. C, Effect of LPS on intraischemic CBF in iNOS-null mice. B, C, The black line below the CBF curves indicates the MCA occlusion period. *p < 0.05 compared with vehicle, LPS plus AG, and AG; ANOVA and Newman–Keuls test; n = 5–7 per group.
J Clin Invest. 2008 January 2; 118(1): 100–110
Figure 4 Detachment sensitizes skin carcinoma cells specifically to TRAIL and CD95L. (A) Subconfluent cells were incubated in the absence (control) or presence of TRAIL (iz-muTRAIL, 1 μg/ml) and/or bortezomib (20 nM) for 24 hours. Cell death was determined by PI staining and flow cytometric analysis. (B and C) Cells were trypsinized and cultured either on an uncoated (attached) or a poly-HEMA–coated surface (detached) in the absence or presence of TRAIL (B; 1 μg/ml) or at the indicated concentrations (C). (D) Subconfluent cells (DT02) were treated with or without 1 μM thapsigargin (Tgg), 30 μg/ml oxaliplatin (Oxp), 5 μg/ml cycloheximide (Chx), or 43°C heat shock (HS) or irradiated with 15 Gy (IR) and were incubated in the absence or presence of TRAIL (1 μg/ml) for 24 hours. (E) Attached (att) or detached (det) cells were incubated in the absence or presence of TRAIL (1 μg/ml) or CD95L (100 ng/ml) for 24 hours. Each data point represents one of the cell lines DT01–DT06 or DT11. The mean percentage of dead WT cells is indicated by a horizontal line. (F) Attached or detached cells were incubated in the absence or presence of TRAIL (1 μg/ml), CD95L (100 ng/ml), 5-FU (200 μg/ml), or etoposide (10 μM) for 24 hours. Standard deviation for duplicates or triplicates is shown. Results are representative of at least 2 independent experiments. J Clin Invest. 2008 January 2; 118(1): 100–110.
